-

11:13:02 AM

PCSA Stock News

PCSA - Processa Pharmaceuticals Inc

08/05/22 3:00 PM

Nasdaq : PCSA

conferenceslow float

Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a

RHEA-AI

neutral

08/04/22 9:30 AM

Nasdaq : PCSA

clinical triallow float

Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces

RHEA-AI

neutral

08/03/22 4:00 PM

Nasdaq : PCSA

clinical triallow float

Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces

RHEA-AI

neutral

07/12/22 8:30 AM

Nasdaq : PCSA

conferenceslow float

Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions announced today

RHEA-AI

very positive

05/12/22 4:20 PM

Nasdaq : PCSA

earningslow float

Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

Processa Pharmaceuticals, Inc. (Nasdaq:

RHEA-AI

neutral

05/05/22 8:30 AM

Nasdaq : PCSA

conferenceslow float

Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a

RHEA-AI

neutral

04/20/22 8:30 AM

Nasdaq : PCSA

clinical triallow float

Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)

Processa f ocuse s on i dentify ing the PCS6422 regimens to i ncrease c apecitabine potency while identifying the MTD of Next Generation Capecitabine The amended p rotocol will provi de a more precise timeline of DPD inhibition and de novo formation while also supplying preliminary data on the us e

RHEA-AI

neutral

04/05/22 8:30 AM

Nasdaq : PCSA

clinical triallow float

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the

RHEA-AI

neutral

03/30/22 4:00 PM

Nasdaq : PCSA

low float

Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a

RHEA-AI

neutral

03/23/22 8:30 AM

Nasdaq : PCSA

conferenceslow float

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a

RHEA-AI

neutral

PCSA Data

IndustryHeavy Duty Truck Manufacturing
Websiteprocessapharmaceuticals.com
Security nameProcessa Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code3531
Employees14
Tags
- Industrial Machinery
- Producer Manufacturing
- Manufacturing
- Heavy Duty Truck Manufacturing

About Processa Pharmaceuticals Inc

Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The Company acquired the assets of Promet Therapeutics, LLC in October of 2017 and assembled a proven regulatory science development team, management team, and Board of Directors. The Processa drug development team members have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. PCS-499 represents the first Processa drug that can potentially be used in several unmet medical need conditions.